New psoriasis drug candidate SHR-1139 begins first human safety check
NCT ID NCT07078695
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a single dose of an experimental drug called SHR-1139 in 24 healthy adults. The main goal is to see how safe the drug is and how the body processes it, not to treat any disease. Participants are healthy men and women aged 18 to 55. The results will help guide future studies in people with psoriasis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linear
Perth, Western Australia, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis